September 30th 2023
Catch up on the top radiology news of the past week.
September 22nd 2023
For patients discharged from the hospital with confirmed COVID-19, median five-month follow-up MRI findings revealed a greater likelihood of regional brain volume reduction, parenchymal lung abnormalities and loss of corticomedullary differentiation in the kidney in comparison to people who have not had COVID-19.
Thirty-five percent of the interventional radiology malpractice cases involved vascular procedures and 26 percent of overall malpractice cases that went to trial resulted in plaintiff judgments with the average award being over $2 million.
The transitional pass-through payment reimbursement code for the FDA-approved PSMA PET agent for prostate cancer detection will be effective as of October 1, according to the Centers for Medicare and Medicare Services (CMS).
For patients who had previous radiotherapy for prostate cancer (PCa), researchers found that a biparametric MRI-based deep learning model demonstrated an 81.5 percent sensitivity rate for PCa recurrence in patients previously treated with external beam radiation treatment (EBRT) and 100 percent sensitivity in patients with greater than 34 ml in gland volumes.
The Pulmonary Embolism (PE) Triage and Notification (PETN) module with RapidAI’s RapidPE platform reportedly demonstrated over 90 percent sensitivity and specificity rates for detection of central PE on computed tomography (CT), according to multicenter study findings presented at the 9th Annual Pulmonary Embolism Symposium.
New research suggests the capability of a mammography-based deep learning model to identify women at high risk of breast cancer led to more than triple the cancer detection rate on breast MRI in comparison to traditional risk assessment tools.
In a study of over 300 patients, researchers saw no significant differences in upgrading or downgrading of prostate cancer assessment on MRI with PI-RADS 2.1 in comparison to PI-RADS 2.0
For cT1 renal masses < 4 cm and renal masses < 2 cm, the PET/CT agent 89Zr-DFO-girentuximab had respective sensitivity rates of approximately 85 percent and 96.7 percent for diagnosing clear cell renal cell carcinoma, according to research recently presented at the European Association of Nuclear Medicine (EANM) 2023 Congress.
The use of automated detection of large vessel occlusion on computed tomography (CT) through artificial intelligence (AI) software reportedly led to an 11.2-minute reduction in triage time from the completion of imaging to initiation of endovascular therapy, according to newly published research.